Clinical Research Directory
Browse clinical research sites, groups, and studies.
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Sponsor: University Medical Center Groningen
Summary
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function. Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whether co-administration with hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2024-07-31
Completion Date
2031-07
Last Updated
2026-02-25
Healthy Volunteers
No
Conditions
Interventions
Hydrochlorothiazide 25 mg
An oral capsule containing 25mg of hydrochlorothiazide
Placebo
A matching oral capsule containing placebo
Locations (12)
Cliniques Universitaires Saint-Luc
Brussels, Belgium
University Hospital Leuven
Leuven, Belgium
Hospital La Cavale Blanche
Brest, France
Necker-Enfants Malades Hospital
Paris, France
Charité University Hospital
Berlin, Germany
University Hospital Cologne
Cologne, Germany
Med. Klinik und Poliklinik III, Universitätsklinikum Dresden.
Dresden, Germany
Amsterdam University Medical Center
Amsterdam, Netherlands
University Medical Center Groningen
Groningen, Netherlands
Erasmus University Medical Center
Rotterdam, Netherlands
Fundación Puigvert
Barcelona, Spain
La Fundación Jiménez Díaz
Madrid, Spain